-+ 0.00%
-+ 0.00%
-+ 0.00%
Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy
Share
Listen to the news

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -

- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending